Literature DB >> 17709483

CD154 tone sets the signaling pathways and transcriptome generated in model CD40-pluricompetent L3055 Burkitt's lymphoma cells.

Ross Stewart1, Wenbin Wei, Anita Challa, Richard J Armitage, John R Arrand, Martin Rowe, Lawrence S Young, Aristides Eliopoulos, John Gordon.   

Abstract

Activated B cells reacting to small amounts of CD40L (CD154) maintain homeostasis by suppressing default apoptosis. Additional outcomes, particularly differentiation, demand higher CD40 occupancy. Here, focusing on survival, we compared changes in the transcriptome of pleiotropically competent, early passage L3055 Burkitt's lymphoma cells confronted with low (picomolar) and high (nanomolar) concentrations of CD154 to gain insight into how a single receptor sets these distinct phenotypes. Of 267 genes altering transcriptional activity in response to strong CD154 tone, only 25 changed coordinately on low receptor occupancy. Seven of the top nine common up-regulated genes were targets of NF-kappaB. Direct measurement and functional inhibition of the NF-kappaB pathway revealed it to be central to a CD40-dependent survival signature. Although the canonical NF-kappaB axis was engaged by both signaling strengths equally, robust alternative pathway activation was a feature selective to a strong CD40 signal. Discriminatory exploitation of the two separate arms of NF-kappaB activation may indicate a principle whereby a cell senses and reacts differentially to shifting ligand availability. Identifying components selectively coupling CD40 to each axis could indicate targets for disruption in B cell pathologies underpinned by ectopic and/or hyper-CD154 activity such as neoplasia and some autoimmunities.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17709483     DOI: 10.4049/jimmunol.179.5.2705

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  DBC1 is a suppressor of B cell activation by negatively regulating alternative NF-κB transcriptional activity.

Authors:  Sinyi Kong; Muthusamy Thiruppathi; Quan Qiu; Zhenghong Lin; Hongxin Dong; Eduardo N Chini; Bellur S Prabhakar; Deyu Fang
Journal:  J Immunol       Date:  2014-10-31       Impact factor: 5.422

2.  CD40 signal expression in gastric cancer tissue and its correlation with prognosis of gastric cancer patients.

Authors:  Rui Li; Wei-Chang Chen; Xue-Qin Pang; Wen-Yan Tian; Wei-Peng Wang; Xue Guang Zhang
Journal:  Mol Biol Rep       Date:  2012-06-22       Impact factor: 2.316

3.  Polypyrimidine tract-binding protein is critical for the turnover and subcellular distribution of CD40 ligand mRNA in CD4+ T cells.

Authors:  Rodrigo Matus-Nicodemos; Stefano Vavassori; Moraima Castro-Faix; Anibal Valentin-Acevedo; Karnail Singh; Valentina Marcelli; Lori R Covey
Journal:  J Immunol       Date:  2011-01-17       Impact factor: 5.422

4.  Primary and malignant cholangiocytes undergo CD40 mediated Fas dependent apoptosis, but are insensitive to direct activation with exogenous Fas ligand.

Authors:  Elizabeth H Humphreys; Kevin T Williams; David H Adams; Simon C Afford
Journal:  PLoS One       Date:  2010-11-17       Impact factor: 3.240

5.  Peripheral blood CD27+ IgG+ B cells rapidly proliferate and differentiate into immunoglobulin-secreting cells after exposure to low CD154 interaction.

Authors:  Jessie F Fecteau; Annie Roy; Sonia Néron
Journal:  Immunology       Date:  2008-11-07       Impact factor: 7.397

6.  A redox state-dictated signalling pathway deciphers the malignant cell specificity of CD40-mediated apoptosis.

Authors:  C J Dunnill; K Ibraheem; A Mohamed; J Southgate; N T Georgopoulos
Journal:  Oncogene       Date:  2016-11-21       Impact factor: 9.867

7.  SUMOylation is required for optimal TRAF3 signaling capacity.

Authors:  Sophia Miliara; Kalliopi K Gkouskou; Tyson V Sharp; Aristides G Eliopoulos
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.